Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Condition:   Extensive-stage Small Cell Lung Cancer Interventions:   Drug: SHR-1316;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Placebo Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials